CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prospectively collected biological data from 97 patients treated...

Full description

Saved in:
Bibliographic Details
Main Authors: Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Myeloma
immunotherapies
resistance
CD200
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226

Similar Items